Tumor suppressor pRb2/p130 gene and its derived product Spa310 spacer domain as perspective candidates for cancer therapy

Journal of Cellular Physiology

Volumn 213, Issue 2, 2007, Pages 403-406

  Giordano, Antonio ^a,b   Rossi, Alessandra ^a,b   Romano, Gaetano ^a   Bagella, Luigi ^a,c  

^a Temple University   (United States)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; PROTEIN P105; PROTEIN P107; PROTEIN P130; RETROVIRUS VECTOR; SPA310 PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL TRANSFORMATION; CELL TYPE; GENE TRANSFER; HOMOZYGOSITY; HUMAN; LIVER CANCER; LUNG CANCER; MULTIGENE FAMILY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL CYCLE; CELL PROLIFERATION; GENES, TUMOR SUPPRESSOR; HUMANS; MULTIGENE FAMILY; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RETINOBLASTOMA-LIKE PROTEIN P130;

EID: 34848898446     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21225     Document Type: Short Survey

References (55)

1. Baffa R, Letko J, McClung C, Le Noir J, Vecchione A, Gomella LG. 2006. Molecular genetics of bladder cancer: Targets for diagnosis and therapy. J Exp Clin Cancer Res 25:145-160.
2. Bagella L, Sun A, Tonini T, Abbadessa G, Cottone G, Paggi M, De Luca A, Claudio PP, Giordano A. 2007. A small molecule based on the pRb2/P130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo. Oncogene 26:1829-1839.
3. Baldi A, De Luca A, Claudio PP, Baldi F, Giordano GG, Tommasino M, Paggi MG, Giordano A. 1995. The Rb2/p130 gene product is a nuclear protein whose phosphorylation is cell cycle regulated. J Cell Biochem 59:402-408.
4. Bates S, Bonetta L, MacAllan D, Parry D, Holder A, Dickson C. 1994. CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene 9:71-79.
5. Buchklovich K, Duffy LA, Harlow E. 1989, The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58:1097-1105.
6. Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, Peterlin BM, Price DH. 2000. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 275:28345-28348.
7. Chen PL, Scully P, Shew JY, Wang JY, Lee WH. 1989. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58:1193-1198.
8. Claudio PP, Howard CM, Baldi A, De Luca A, Fu Y, Condorelli G, Sun Y, Colburn N, Calabretta B, Giordano A. 1994. P130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res 54:5556-5560.
9. Claudio PP, De Luca A, Howard CM, Baldi A, Firpo EJ, Koff A, Paggi MG, Giordano A. 1996. Functional analysis of pRb2/p130 interaction with cyclins. Cancer Res 56:2003-2008.
10. Claudio PP, Howard CM, Pacilio C, Cinti C, Romano G, Minimo C, Maraldi NM, Minna JD, Gelbert L, Leoncini L, Tosi GM, Micheli P, Caputi M, Giordano GG, Giordano A. 2000. Mutations in the retinoblastoma-relatedgene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res 60:372-382.
11. DiMaio D, Lai CC, Klein O. 1998. Virocrine transformation: The intersection between viral transforming proteins and cellular signal transduction pathways. Annu Rev Microbiol 52:397-421.
12. Drummond-Barbosa D, DiMaio D. 1997. Virocrine transformation. Biochim Biophys Acta 1332:M1-17.
13. Ewen ME, Xing YG, Lawrence JB, Livingston DM. 1991. Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein. Cell 66:1155-1164.
14. Fischer PM, Giannella-Borradori A. 2003. CDK inhibitors in clinical development for the treatment of cancer. Expert Opin Invest Drugs 12:955-970.
15. Fujii S, Tominaga O, Nagawa H, Tsuno N, Nita ME, Tsuruo T, Muto T. 1998. Quantitative analysts of the cyclin expression in human esophageal cancer cell lines. J Exp Clin Cancer Res 17:491-496.
16. Gan DD, Macaluso M, Cinti C, Khalili K, Giordano A. 2003. How does a normal human cell become a cancer cell? J Exp Clin Cancer Res 22:509-516.
17. Giordano A, Whyte P, Harlow E, Franza BR Jr, Beach D, Draetta G. 1989. A 60 kd cdc2-associated polypetide complexes with the E1A proteins in adenovirus-infected cells. Cell 58:981-990.
18. Giordano A, Lee JH, Scheppler JA, Herrmann C, Harlow E, Deuschle U. 1991. Cell cycle regulation of histone H1 kinase activity associated with the adenoviral protein E1A. Science 253:1271-1275.
19. Giordano A, Fucito A, Romano G, Marino IR. 2007. Carcinogenesis and environment: The cancer stem cell hypothesis and implicationsforthe development of novel therapeutics and diagnostics. Front Biosci 12:3475-3482.
20. Gu Y, Rosenblatt J, Morgan DO. 1992. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J 11:3995-4005.
21. Hannon GJ, Demetrick D, Beach D. 1993. Isolation of the Rb-related p130 through its interaction with CDK2 and cyclins. Genes Dev 7:2378-2391.
22. Harwell RM, Mull B, Porter DC, Keyomarsi K. 2004. Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells. J Biol Chem 279:12695-12705.
23. Huang HJ, Yee JK, Shew JY, Chen PL, Bookstein R, Friedman T, Lee EY, Lee WH. 1988. Suppression of the neoplastic phenotype by replacement of the retinoblastoma gene product in human cancer cells. Science 242:1563-1566.
24. Ioachim E, Peschos D, Goussa A, Mittari E, Charalabopoulos K, Michael M, Salmas M, Vougiouklakis T, Assimakopoulos D, Agnantis NJ. 2004. Expression patterns of cyclins D1, E in laryngeal epithelial lesions: Correlation with other cell cycle regulators (p53, pRb, Ki-67 and PCNA) and clinicopathological features. J Exp Clin Cancer Res 21:321-327.
25. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV. 1994. Cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
26. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S. 1992. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 257:1689-1694.
27. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. 1987. Human retinoblastoma susceptibility gene: Cloning, identification, and sequence. Science 235:1394-1399.
28. Lees JA, Buchkovich KJ, Marshak DR, Anderson CW, Harlow E. 1991. The retinoblastoma protein is phosphorylated on multiple sites by human cdk2. EMBO J 10:4279-4290.
29. Li Y, Graham C, Lacy S, Duncan AM, Whyte P. 1993. The adenovirus E1a-associated 130-kD protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and E. Genes Dev 7:2366-2377.
30. Li Y, Chinni SR, Senderowicz AM, Sarkar FH. 2000. Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. Int J Cancer 108:654-664.
31. Liao C, Li S, Wang X, Muhlrad S, Bjartell A, Wolgemuth DJ. 2004. Elevated levels and distinct patterns of expression of A-type cyclins and their associated cyclin-dependent kinases in male germ cell tumors. Int J Cancer 108:654-664.
32. MacLachlan TK, Sang N, Giordano A. 1995. Cyclins, cyclin-dependent kinases and cdk inhibitors: Implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 5:127-156.
33. Malumbers M, Barbacid M. 2005. Mammalian cyclin-dependent kinases. Trends Biochem Sci 30:630-641.
34. Mayol X, Grana X, Baldi A, Sang N, Hu Q, Giordano A. 1993. Cloning of a new member ofthe retinoblastoma gene family (pRb2), which binds to the E1A transforming domain. Oncogene 8:2561-2566.
35. Mihara K, Cao XR, Yen A, Chandler S, Driscoll B, Murphree AL, T'Ang A, Fung YK. 1989. Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 246:1300-1303.
36. Nobori T, Miura K, Wu DJ, Takabayashi K, Carson DA. 1994. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756.
37. Ohtsubo M, Theodoras AM, Schumacher J, Roberts J, Pagano M. 1995. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15:2612-2624.
38. Pepper C, Thomas A, Hoy T, Fegan C, Bentley P. 2001. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukemia. Br J Haematol 114:70-77.
39. Peschos D, Stefanou D, Vougiouklakis T, Assimakopoulos DA, Agnantis NJ. 2005. Cell cycle proteins in laryngeal cancer: Role in proliferation and prognosis. J Exp Clin Cancer Res 24:431-437.
40. Resnitzky D, Reed SI. 1995. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol 15:3463-3469.
41. Romano G. 2003. The complex biology of the receptor for the insulin-like growth factor-1. Drug News & Perspect 16:525-531.
42. Romano G. 2005. The role of adult stem cells in carcinogenesis. Drug News Perspect 18:555-559.
43. Romano G. 2006a. The controversial role of adenoviral-derived vectors in gene therapy programs: Where do we stand? Drug News Perspect 19:99-106.
44. Romano G. 2006b. Advances and perspectives in the field of gene transfer technology. Drug News Perspect 19:359-368.
45. Romano G. 2007. The standpoint of gene therapy programs: A report on the tenth annual meeting of the American Society of Gene Therapy. Drug News Perspect (in press).
46. Romano G, Prisco M, Zanocco-Marani T, Peruzzi F, Valentinis B, Baserga R. 1999. Dissociation between resistance from apoptosis and the transformed cell phenotype in IGF-1 receptor signaling. J Cell Biochem 72:294-310.
47. Roth JA, Cristiano RJ. 1997. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 85:546-553.
48. Shirodkar S, Ewen M, DeCaprio JA, Morgan J, Livingston DM, Chittenden T. 1992. The transcription factor E2F interacts with the retinoblastoma product and p107 cyclin A complex in a cell cycle regulated manner. Cell 68:157-166.
49. Soddu S, Sacchi A. 1997. P53 role in DNA re pair and tumorigenesis. J Exp Clin Cancer Res 16:237-242.
50. Sunters A, Thomas DP, Yeudall WA, Grigoriadis AE. 2004. Accelerated cell cycle progression in osteoblasts overexpressing the c-fos proto-oncogene: Induction of cyclin A and enhanced CDK2 activity. J Biol Chem 279:9882-9891.
51. Tenderenda M. 2005. A study on the prognostic value of cyclins D1 and E expression levels in respectable gastric cancer and on some correlations between cyclins expression, histoclinical parameters and selected protein products of cell-cycle regulatory genes. J Exp Clin Cancer 24:405-414.
52. Weinberg RA. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-330.
53. Xiong Y. 1996. Why are there so many CDK inhibitors? Biochim Biophys Acta 1288:1-5.
54. Yeung RS, Bell DW, Testa JR, Mayol X, Baldi A, Grana X, Klinga-Levan K, Knudson AG, Giordano A. 1993. The retinoblastoma-related gene, Rb2, maps to a human chromosome 16q12 abd rat chromosome 19. Oncogene 8:3465-3488.
55. Zhu L, van der Heuvel S, Helin K, Fattaey A, Ewen M, Livingston D, Dyson N, Harlow E. 1993. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev 7:1111-1125.